Although the reported rates of HER-2 overexpression appear to be variable, there is a general agreement with regard to a higher HER-2 positivity in gastroesophageal junction cancer (24–35%) compared with gastric carcinoma (9.5–21%) (11–13). Here, ERBB2 is linked to gastric carcinoma.